2.
竞争风险模型分析结果
Results of competitive risk model analysis
| Parameter | Univariate analysis | Model 1# | Model 2＄ | ||||||||
| β | HR | P | β | HR | P | β | HR | P | |||
| #: Model 1 was adjusted for age $: Model 2 was adjusted for age, ATD history, dose of131I, thyroid volume, SWE and TRAb. HR: Hazard ratio; ATD: Anti-thyroid drugs; SWE: Shear wave elastic velocity value; FT3: Free triiodothyronine; FT4: Free thyroxinef; TRAb: Thyrotrophin receptor antibody. | |||||||||||
| Ki67 | -0.91 | 0.40 (0.19, 0.85) | 0.017 | -1.17 | 0.31 (0.13, 0.73) | 0.007 | -1.04 | 0.36 (0.15, 0.86) | 0.022 | ||
| Age | -0.02 | 0.98 (0.95, 1.00) | 0.066 | -0.04 | 0.97 (0.93, 1.00) | 0.030 | -0.02 | 0.98 (0.95, 1.01) | 0.240 | ||
| Gender | -0.25 | 0.78 (0.35, 1.75) | 0.550 | - | - | - | - | - | - | ||
| Course of GD | < 0.01 | 1 (1.00, 1.01) | 0.500 | - | - | - | - | - | - | ||
| ATD history | 0.57 | 1.77 (0.74, 4.23) | 0.200 | - | - | - | 0.15 | 1.17 (0.43, 3.15) | 0.760 | ||
| Dose of 131I | 0.11 | 1.12 (0.93, 1.35) | 0.230 | - | - | - | -0.21 | 0.81 (0.68, 0.96) | 0.017 | ||
| Thyroid volume | 0.08 | 1.09 (1.06, 1.11) | < 0.001 | - | - | - | 0.10 | 1.11 (1.07, 1.15) | < 0.001 | ||
| SWE | -1.32 | 0.27 (0.08, 0.84) | 0.025 | - | - | - | -0.93 | 0.40 (0.11, 1.42) | 0.150 | ||
| FT3 | < -0.01 | 1.00 (0.96, 1.03) | 0.810 | - | - | - | - | - | - | ||
| FT4 | < -0.01 | 1.00 (0.97, 1.02) | 0.720 | - | - | - | - | - | - | ||
| TRAb | -0.05 | 0.95 (0.90, 1.00) | 0.054 | - | - | - | -0.02 | 0.98 (0.93, 1.02) | 0.310 | ||